ライフサイエンスコーパス: metronidazole

1 d intra-abdominal infections (when used with metronidazole).

2 f antibiotic treatment (ciprofloxacin and/or metronidazole).

3 be favored (eg, carbapenems, quinolones, and metronidazole).

4 and a 7-day prescription of amoxicillin and metronidazole.

5 e charge in mice faeces 1-2-fold faster than metronidazole.

6 biotics, but ceased following treatment with metronidazole.

7 played by the combination of amoxicillin and metronidazole.

8 dvised prophylaxis with a cephalosporin plus metronidazole.

9 hoc combination of data for amoxicillin and metronidazole.

10 , toxin-binding polymer, with vancomycin and metronidazole.

11 or same-day FDIS, with or without adjunctive metronidazole.

12 ated with the combination of paromomycin and metronidazole.

13 ad no specific benefit from amoxicillin plus metronidazole.

14 e of intravenous beta-lactam antibiotic plus metronidazole.

15 imes more potent against E. histolytica than metronidazole.

16 cocci infection at 3 or 6 months compared to metronidazole.

17 naffected by resistance to clarithromycin or metronidazole.

18 because they had a mild allergic reaction to metronidazole.

19 doxin oxidoreductase and may be sensitive to metronidazole.

20 risk in the control group, and lower in the metronidazole (1.41/person-year; p = 0.004), Ecologic Fe

21 ot differ significantly (P = .8) between the metronidazole (-1.8 CI, [-2.5, -1.1]) and the placebo gr

22 lindamycin (100% resistant to 2 mug/mL), and metronidazole (100% resistant to 4 mug/mL).

23 tro subgingival biofilm model was exposed to metronidazole (15 mug/mL), amoxicillin (15 mug/mL), metr

24 ) for clarithromycin, 44% (95% CI 39-48) for metronidazole, 18% (95% CI 15-22) for levofloxacin, 3% (

25 Treatment relies on metronidazole(2), which has adverse effects(3), and pote

26 d to one of four treatment groups: 1) FDIS + metronidazole; 2) FDIS + placebo; 3) SRP + metronidazole

27 ted to one of four treatment groups: 1) FDIS+metronidazole; 2) FDIS+placebo; 3) SRP+metronidazole; or

28 comycin 125 mg every 6 hours for 10 days, or metronidazole 375 mg every 6 hours for 10 days.

29 months and randomized to treatment with oral metronidazole 500 mg twice daily for 7 days or observati

30 of oral levofloxacin (500 mg once daily) and metronidazole (500 mg 3 times per day).

31 d either ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 hours or meropenem (1 g)

32 gned to receive oral cephalexin, 500 mg, and metronidazole, 500 mg (n = 202 participants), vs identic

33 All 450 participants received oral metronidazole (7 days) and were equally randomized to va

34 to receive vaginal suppositories containing metronidazole 750 mg plus miconazole 200 mg or matching

35 cent vaginal infection received intravaginal metronidazole 750 mg plus miconazole 200 mg or placebo f

36 nited States and Kenya received intravaginal metronidazole (750 mg) plus miconazole (200 mg) or place

37 oncomitant administration of amoxicillin and metronidazole adjunctive to SRP in adults who are otherw

38 erococcal domination was increased 3-fold by metronidazole administration, whereas domination by Prot

39 ncomycin were compared to those treated with metronidazole after balancing on patient characteristics

40 and amoxicillin alone or in combination with metronidazole, albeit by less than 1 log.

41 Metronidazole alone did not affect biofilm composition.

42 i-E. histolytica MIF antibodies, compared to metronidazole alone.

43 ibiotics was found to be more efficient than metronidazole alone; however, only minor differences in

44 0-to-14-day course of empirical therapy with metronidazole, alone or in combination with a fluoroquin

45 vere periodontitis (n = 24), amoxicillin and metronidazole (AM) were prescribed for 7 days.

46 vere periodontitis (N = 24), amoxicillin and metronidazole (AM) were prescribed for 7 days.

47 gic, and immunologic benefits of amoxicillin/metronidazole (AM) when performing full-mouth ultrasonic

48 They are generally resistant to metronidazole, aminoglycosides and ciprofloxacin with L.

49 e randomly assigned to either 7 d of peroral metronidazole/amoxicillin AB treatment or no AB, along w

50 d microbiological responses of amoxicillin + metronidazole (AMX + MET) versus clarithromycin (CLM) as

51 The systemic use of combined amoxicillin and metronidazole (AMX/MET) as an adjunctive treatment to fu

52 The combination of Amoxicillin and metronidazole (AMX/MET) as an adjunctive treatment to sc

53 nt fractions and potentiates the activity of metronidazole, an antimicrobial agent used in the treatm

54 sitivity rate of 71.4% (CI, 29.0%-96.3%) for metronidazole and 83.3% (CI, 35.8%-99.5%) for ornidazole

55 Metronidazole and a follow up imaging at 3 months showed

56 dazole (15 mug/mL), amoxicillin (15 mug/mL), metronidazole and amoxicillin in combination, doxycyclin

57 Mechanical treatment associated with metronidazole and amoxicillin promoted a beneficial chan

58 d with scaling and root planing and systemic metronidazole and amoxicillin.

59 Metronidazole and carbapenems exhibited reliable activit

60 tion/pregnancy, sexual risk-taking, and age, metronidazole and Ecologic Femi+ users, each compared to

61 und Methanobrevibacter oralis susceptible to metronidazole and fusidic acid.

62 % (23/26) in the ceftolozane/tazobactam plus metronidazole and meropenem groups, respectively, and 10

63 esses, in whom antibiotic therapy comprising metronidazole and meropenem was partly beneficial in imp

64 l cure rates with ceftazidime-avibactam plus metronidazole and meropenem, respectively, were as follo

65 s treated with ronidazole, dimetridazole and metronidazole and non-medicated animals (controls), at t

66 This study compared dual therapy with IV metronidazole and oral vancomycin versus vancomycin mono

67 Dual therapy with IV metronidazole and oral vancomycin was common for non-ful

68 test (BAT) for the diagnosis of IHRs due to metronidazole and ornidazole and to determine possible c

69 No cross-reactivity between metronidazole and ornidazole in IHRs exists.

70 Metronidazole and other 5-nitroimidazoles (5-NI) are amo

71 Of 96 participants, 48 were allocated to the metronidazole and placebo group each.

72 al success of tolevamer was inferior to both metronidazole and vancomycin (P < .001), and metronidazo

73 ignificant differences were observed between metronidazole and vancomycin (reference) for all-cause m

74 The relative impacts of metronidazole and vancomycin on the intestinal microbiot

75 this study, we compared dual therapy with IV metronidazole and vancomycin vs vancomycin monotherapy.

76 Dual therapy with IV metronidazole and vancomycin was common for nonfulminant

77 s L. rhamnosus and L. casei are resistant to metronidazole and vancomycin.

78 ome at any point, and decreased equally with metronidazole and vancomycin.

79 nitiated with benzylpenicillin, clindamycin, metronidazole and vancomycin.

80 ild CDI, clinical outcomes were similar with metronidazole and vancomycin.

81 mptomatic BV patients were treated with oral metronidazole and were evaluated at cessation of treatme

82 estigated the effect of brief treatment with metronidazole and/or oral vancomycin on susceptibility t

83 rile neutropenia that included cefepime (+/- metronidazole) and piperacillin-tazobactam and a clinica

84 The initial treatment in 82% of patients was metronidazole, and 18% experienced treatment failure.

85 63 patients received tolevamer, 289 received metronidazole, and 266 received vancomycin.

86 20 study subjects, 101 (84%) were started on metronidazole, and 33 of those (33%) were subsequently g

87 hromycin, the combination of Amoxicillin and Metronidazole, and Amoxicillin were the three most commo

88 were cefoxitin sodium, cefazolin sodium with metronidazole, and ampicillin sodium-sulbactam sodium, r

89 outine prophylaxis with a cephalosporin plus metronidazole, and did not have an infection at the time

90 n efficacy is Lactobacillus sequestration of metronidazole, and efficacy decreases when the relative

91 uding cefazolin/metronidazole, ciprofloxacin/metronidazole, and ertapenem.

92 t antibiotics used to treat CDI (vancomycin, metronidazole, and fidaxomicin) is a desired trait in su

93 th clavulanate, ampicillin, chloramphenicol, metronidazole, and penicillin were determined using a gr

94 In contrast, vancomycin, metronidazole, and rifaximin (at similar sub-MICs) did n

95 netics was compared with that of vancomycin, metronidazole, and rifaximin.

96 polymyxin B, and Abx (ampicillin, neomycin, metronidazole, and vancomycin).

97 + metronidazole; 2) FDIS + placebo; 3) SRP + metronidazole; and 4) SRP + placebo.

98 enzymatic prodrug therapy with conventional metronidazole antibiotics.

99 Our results suggest that oral vancomycin and metronidazole are equally likely to impact patients' ris

100 Vancomycin and metronidazole are first-line therapies for most patients

101 rate that vancomycin, and to a lesser extent metronidazole, are associated with marked intestinal mic

102 cited at 365nm which quenched in presence of Metronidazole as a template molecule..

103 erapy using a combination of amoxicillin and metronidazole as an adjunct to SRP can enhance the clini

104 Hinton agar and to the inhibitory effects of metronidazole at 16 mg/L in an enriched Brucella blood a

105 amycin at 4 mg/L, doxycycline at 4 mg/L, and metronidazole at 16 mg/L, with a post hoc combination of

106 to ciprofloxacin, and 90% were resistant to metronidazole at 16 mg/L.

107 ionally evaluated for in vitro resistance to metronidazole at 4 mug/mL.

108 otaxime (AC), or ampicillin, tobramycin, and metronidazole (ATM).

109 fotaxime (AC), or ampicillin, tobramycin and metronidazole (ATM).

110 ere treated with broad-spectrum antibiotics (metronidazole, ciprofloxacin) after transplantation.

111 ed with lower SSI rates, including cefazolin/metronidazole, ciprofloxacin/metronidazole, and ertapene

112 (proton pump inhibitor [PPI] + amoxicillin + metronidazole + clarithromycin [PAMC]) and traditional b

113 ceptibility testing of H. pylori isolates to metronidazole, clarithromycin, amoxicillin, and tetracyc

114 Resistance to metronidazole, clarithromycin, and levofloxacin is more

115 The prevalence of metronidazole, clarithromycin, and levofloxacin resistan

116 These inhibitors are effective against metronidazole-, clarithromycin-, and rifampicin-resistan

117 py) vs oral vancomycin with intravenous (IV) metronidazole (combination therapy).

118 While first-line antibiotic treatment (metronidazole) commonly kills the protozoan pathogen, it

119 r samples treated with either amoxicillin or metronidazole compared with controls (P <0.05).

120 d clinical outcomes among those treated with metronidazole compared with vancomycin, using Cox propor

121 rative 48-hour course of oral cephalexin and metronidazole, compared with placebo, reduced the rate o

122 nsoprazole, amoxicillin, clarithromycin, and metronidazole (concomitant therapy); or 5 days of lansop

123 nsoprazole, amoxicillin, clarithromycin, and metronidazole (concomitant).

124 nd used as a selective fluorescent probe for Metronidazole detection.

125 The limit of detection for metronidazole determination was obtained 0.15muM.

126 tment of asymptomatic BV with 1 week of oral metronidazole did not decrease the incidence of gonorrhe

127 Amoxicillin plus metronidazole did not significantly affect the resistanc

128 dontal therapy supplemented with amoxicillin-metronidazole during either the non-surgical or the surg

129 or counseling plus intermittent use of oral metronidazole, Ecologic Femi+ vaginal capsule (containin

130 d OP-1118 (unlike vancomycin, rifaximin, and metronidazole) effectively inhibited sporulation by C. d

131 ncreased incidence of childhood cancer among metronidazole-exposed children (adjusted relative risk,

132 reported no significant association between metronidazole exposure and congenital malformations (odd

133 ntamoeba histolytica, which was treated with metronidazole, followed by eradication therapy with paro

134 by combination rifampicin, moxifloxacin, and metronidazole for 6 months is effective.

135 ived FMUD and 375 mg amoxicillin plus 250 mg metronidazole for 7 days.

136 al cure rate with ceftazidime-avibactam plus metronidazole for ceftazidime-resistant infections was c

137 Current recommendations include metronidazole for treatment of mild to moderate CDI and

138 Both vancomycin and metronidazole further suppressed microbiome components d

139 is and who had completed a course of vaginal metronidazole gel as part of the eligibility requirement

140 s benefit specifically from amoxicillin plus metronidazole given as an adjunct to full-mouth scaling

141 agnosed in 13 women (6.4%) in the cephalexin-metronidazole group vs 31 women (15.4%) in the placebo g

142 D. fragilis was significantly greater in the metronidazole group, although it declined rapidly from 6

143 Metronidazole had a significant, adjunctive effect in pa

144 56.0% of patients received ceftriaxone with metronidazole (hospital range: 0%-100%) and 44.0% receiv

145 o corticosteroids, infliximab or adalimumab, metronidazole, hospitalizations, higher ambulatory care

146 ntileishmanial agents, a series of quinoline-metronidazole hybrid compounds was synthesized and teste

147 It may be concluded that amoxicillin/metronidazole improves clinical and microbiologic result

148 CDI was treated with metronidazole in 12 children, vancomycin in 6, and both

149 ing was proportional to the concentration of Metronidazole in a linear range of at least 0.2muM to 15

150 A novel optical nanosensor for detection of Metronidazole in biological samples was reported.

151 alf-life, over 2-5 min (combined with 500 mg metronidazole in colorectal surgery).

152 bination therapy with oral vancomycin and IV metronidazole in critically ill patients with CDI.

153 the clinical and microbiological efficacy of metronidazole in Danish children.

154 ull-dose proton-pump inhibitor and high-dose Metronidazole in group A, and full-dose proton-pump inhi

155 al treatment associated with amoxicillin and metronidazole in individuals with aggressive periodontit

156 treatment failures have been associated with metronidazole in severe or complicated cases of CDI.

157 gested that prescription of amoxicillin plus metronidazole in the context of periodontal therapy shou

158 umvent the resistance mechanism that renders metronidazole ineffectiveness in drug resistance cases o

159 Metronidazole inhibits the ferredoxin/hydrogenase pathwa

160 Metronidazole is appropriate for mild disease.

161 ization of naturally abundant (15)N sites in metronidazole is demonstrated using SABRE-SHEATH (Signal

162 se proton-pump inhibitor and higher doses of Metronidazole is essential to achieve such results.

163 Metronidazole is often used for treatment, though eradic

164 Metronidazole is suboptimal for nonsevere CDI as it is l

165 Ceftriaxone combined with metronidazole is superior to cefoxitin alone in preventi

166 Metronidazole is the drug of choice.

167 Metronidazole is the first-line treatment; however, trea

168 d, which may be of substantial importance as metronidazole is widely used in human medicine.

169 PPI + clarithromycin + either amoxicillin or metronidazole) is restricted to areas with known low cla

170 y, 26%; Spain, 19.5%), 33% were resistant to metronidazole (Italy, 33%; Spain, 34%), and 8.8% were re

171 t associated with the use of amoxicillin and metronidazole led to an improvement in all clinical para

172 The application of metronidazole led to retractions of major processes asso

173 ower than the five antibiotics, amoxicillin, metronidazole, levofloxacin, tetracyclin, and clarithrom

174 rythromycin < tetracyclines < azithromycin < metronidazole < amoxicillin + clavulanic acid < clarithr

175 These data suggest that metronidazole may be considered for the treatment of ini

176 n delivery, prophylactic oral cephalexin and metronidazole may be warranted.

177 Metronidazole may still be an appropriate therapeutic op

178 infection (FDIS), with or without adjunctive metronidazole (MET).

179 crobiologic effects of the adjunctive use of metronidazole (MTZ) and amoxicillin (AMX) in the treatme

180 Metronidazole (MTZ) is often used in combination therapi

181 rial (RCT) evaluating the 2-years effects of metronidazole (MTZ) plus amoxicillin (AMX) as adjuncts t

182 This enzyme converts the innocuous prodrug metronidazole (MTZ) to a cytotoxin.

183 Bath application of metronidazole (Mtz) to fish expressing nitroreductase (N

184 ams) or 7-day (500 mg twice daily) multidose metronidazole (MTZ) treatment.

185 Metronidazole (MTZ), which has activity only against ana

186 Antibiosis with Ciprofloxacin/Metronidazole (n = 12, P = .01), Piperacillin/Tazobactam

187 Treatment with metronidazole, nitazoxanide, and albendazole failed to e

188 For metronidazole, nonsense mutations and R16H substitutions

189 nd systemically administered amoxicillin and metronidazole or as GR (n = 30) based on mean attachment

190 Polymersome-encapsulated metronidazole or doxycycline significantly (P<0.05) redu

191 Polymersome-encapsulated metronidazole or doxycycline, free metronidazole, or dox

192 00 mg of oral doxycycline and 400 mg of oral metronidazole or identical placebos.

193 on code for CDI (008.45), and treatment with metronidazole or oral vancomycin > 3 days after admissio

194 ents were included if they were treated with metronidazole or oral vancomycin and had no history of V

195 Metronidazole or oral vancomycin can cure C. difficile i

196 on in a 1:1 ratio to a 10-day course of oral metronidazole or placebo.

197 ontrol and root planing plus amoxicillin and metronidazole or to a control treatment group (CTG) (n =

198 Patients with symptomatic CDI taking metronidazole or vancomycin were enrolled.

199 ed metronidazole with vancomycin; 8 compared metronidazole or vancomycin with another agent, combined

200 linically recovered following treatment with metronidazole or vancomycin, oral administration of spor

201 istant in vitro to doxycycline, amoxicillin, metronidazole, or clindamycin, in 55%, 43.3%, 30.3%, and

202 apsulated metronidazole or doxycycline, free metronidazole, or doxycycline, or polymersomes alone as

203 th increasing concentrations of amoxicillin, metronidazole, or their combination and incubated anaero

204 FDIS+metronidazole; 2) FDIS+placebo; 3) SRP+metronidazole; or 4) SRP+placebo.

205 er-quality evidence is available for topical metronidazole, oral tetracycline, laser and light-based

206 nd had successfully completed treatment with metronidazole, oral vancomycin, or both at 44 study cent

207 d negative predictive value (NPV) of STs for metronidazole/ornidazole were 33.3%/16.6%, 94.2%/97.3%,

208 ore likely than male patients to demonstrate metronidazole (P < 0.05) and clarithromycin (P < 0.05) r

209 enems (p=0.0013), vancomycin (p=0.0040), and metronidazole (p=0.0004) following the intervention.

210 success, the two groups receiving adjunctive metronidazole performed significantly better than the tw

211 nce of potentially interfering drugs such as metronidazole, phenobarbital, chlorpheniramine maleate,

212 eatment groups: group A, antibiotics (500 mg metronidazole plus 375 mg amoxicillin three times per da

213 Monthly treatment with intravaginal metronidazole plus miconazole reduced the proportion of

214 H2 receptor blockers, plus clarithromycin or metronidazole, plus amoxicillin or tetracycline, with or

215 a colon cancer xenograft with the antibiotic metronidazole reduced Fusobacterium load, cancer cell pr

216 In vitro testing for metronidazole resistance was also performed on 25/47 iso

217 Metronidazole resistance was demonstrated in isolates fr

218 l clarithromycin resistance, while levels of metronidazole resistance were similar in all multilocus

219 Of 25 test of cure isolates tested for metronidazole resistance, 0/10 TVV+ isolates demonstrate

220 fections in areas of high clarithromycin and metronidazole resistance.

221 patient demographics, clinical outcomes, and metronidazole resistance.

222 ith clinical symptoms, repeat infections, or metronidazole resistance.

223 R16H mutations have utility for determining metronidazole resistance.

224 l), 10/247 isolates tested were resistant to metronidazole (resistance breakpoint >/= 32 mug/ml), and

225 s against both metronidazole-susceptible and metronidazole-resistant G. lamblia isolates, and their e

226 The Giardia viability studies in the metronidazole-resistant strain and the G. lamblia CK irr

227 use of Lactin-V after treatment with vaginal metronidazole resulted in a significantly lower incidenc

228 Although metronidazole resulted in transient loss of colonization

229 Treating transgenic adults with metronidazole resulted in two rod cell death models.

230 Tetracycline, erythromycin, clindamycin, and metronidazole revealed poor in vitro activity against hu

231 ficant, adjunctive effect in patients with a metronidazole-sensitive subgingival microbiota on the cl

232 5 days of lansoprazole, clarithromycin, and metronidazole (sequential therapy).

233 d by 5-day lansoprazole, clarithromycin, and metronidazole (sequential); or 5-day lansoprazole, amoxi

234 ad and emphasize the importance of quinoline-metronidazole series as a suitable platform for the futu

235 All strains were ciprofloxacin resistant and metronidazole susceptible, and 8.3% and 13.0% of the iso

236 nalog, thiram, their activities against both metronidazole-susceptible and metronidazole-resistant G.

237 l bismuth quadruple therapy (PPI + bismuth + metronidazole + tetracycline [PBMT]).

238 accessible anastomosis, received 3 months of metronidazole therapy.

239 ance to clarithromycin, levofloxacin, and/or metronidazole; these drugs, if used previously, should b

240 ients received 375 mg amoxicillin and 500 mg metronidazole three times per day for 7 days during the

241 lemented with 375 mg amoxicillin plus 500 mg metronidazole, three times daily for 7 days.

242 c antibiotics (375 mg amoxicillin and 500 mg metronidazole, three times daily) or placebo for 7 days.

243 ton-Pump Inhibitor + Clarithromycin 500 mg + Metronidazole/Tinidazole 500 mg bid/tid in the following

244 g a bacterial nitroreductase, which converts metronidazole to a cytotoxin, specifically in podocytes

245 noninferiority of ceftazidime-avibactam plus metronidazole to meropenem in the microbiologically modi

246 Guidelines recommend adding intravenous (IV) metronidazole to oral vancomycin for fulminant Clostridi

247 patocytes were depleted by administration of metronidazole to Tg(fabp10a:CFP-NTR) animals.

248 Application of the prodrug metronidazole to the transgenic fish induces acute damag

249 In metronidazole-treated myl7:nitroreductase embryos, myoca

250 e likely to develop VRE within 3 months than metronidazole-treated patients (adjusted relative risk,

251 e likely to develop VRE within 3 months than metronidazole-treated patients (adjusted RR 0.96, 95% CI

252 the risk of VRE following oral vancomycin or metronidazole treatment among patients with CDI.

253 Metronidazole treatment amplified these proinflammatory

254 surements of 11 key bacterial species during metronidazole treatment for 15 cases of BV.

255 Recurrence after metronidazole treatment is high.

256 s do not provide evidence to support routine metronidazole treatment of D. fragilis positive children

257 clinical trial to assess the impact of oral metronidazole treatment on the genital immune parameters

258 recurrence when performed shortly after oral metronidazole treatment, with both 90% positive predicti

259 r groups (n = 17/group) after seven-day oral metronidazole treatment: behavioral counseling only (con

260 t predicts bacterial growth as a function of metronidazole uptake, sensitivity, and metabolism.

261 Amoxicillin/metronidazole used as an adjunct to the FMUD protocol ad

262 o hyperpolarized more distant (15)N sites in metronidazole using longer-range spin-spin couplings (J(

263 Oral antibiotics such as metronidazole, vancomycin and fidaxomicin are therapies

264 a population with a median age of 65 years: metronidazole, vancomycin, fidaxomicin, and fecal microb

265 h high dose kanamycin, gentamicin, colistin, metronidazole, vancomycin, individually or in a combinat

266 onstrate clinical success rates of 66.3% for metronidazole vs 78.5% for vancomycin for severe CDI.

267 who receive prophylactic oral cephalexin and metronidazole vs placebo for 48 hours following cesarean

268 clinical trial comparing oral cephalexin and metronidazole vs placebo for 48 hours following cesarean

269 ess in patients with severe CDI who received metronidazole was 66.3% compared with vancomycin, which

270 In the multivariable model, ceftriaxone with metronidazole was associated with a 90% reduction in the

271 imit of detection (2.0 log10 CFU/g), whereas metronidazole was associated with mean C. difficile coun

272 safety profile of ceftazidime-avibactam plus metronidazole was consistent with that previously observ

273 sified as having received dual therapy if IV metronidazole was given within the same time window, and

274 sified as having received dual therapy if IV metronidazole was given within the same time window, and

275 metronidazole and vancomycin (P < .001), and metronidazole was inferior to vancomycin (P = .02; 44.2%

276 inferior to antibiotic treatment of CDI, and metronidazole was inferior to vancomycin.

277 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem across all pr

278 Treatment with ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in adult pati

279 Ceftolozane/tazobactam plus metronidazole was noninferior to meropenem in the primar

280 Ceftazidime-avibactam plus metronidazole was noninferior to meropenem in the treatm

281 A nonrecommended antibiotic (metronidazole) was associated with decreases in anaerobe

282 Among 3656 patients treated with metronidazole, we identified 3282 patients with success

283 First, among those treated with metronidazole, we identified predictors of success, defi

284 Fidaxomicin and metronidazole were both dominated by FMT colonoscopy.

285 acy and safety of ceftazidime-avibactam plus metronidazole were compared with meropenem in 1066 men a

286 e significantly reduced in mice treated with metronidazole when combined with anti-E. histolytica MIF

287 ot planing (SRP), with or without adjunctive metronidazole, when treating chronic destructive periodo

288 With the exception of metronidazole (which was observed at less than 3% relati

289 c rifampicin, as well as with the antibiotic metronidazole, which targets hypoxic bacterial populatio

290 pathogens resistant to both amoxicillin and metronidazole, which were mostly either S. constellatus

291 amoxicillin alternatives, clarithromycin and metronidazole, while significantly worse than amoxicilli

292 ting of stable CDI incidence, replacement of metronidazole with oral vancomycin is unlikely to be a s

293 ting of stable CDI incidence, replacement of metronidazole with oral vancomycin is unlikely to be a s

294 ubgroup analysis of a single study comparing metronidazole with vancomycin for patients who have seve

295 Three trials compared metronidazole with vancomycin; 8 compared metronidazole

296 with systemic antibiotics, and Ciprofloxacin/Metronidazole with/without systemic antibiotics).

297 crobiome diversity compared to Ciprofloxacin/Metronidazole with/without systemic antibiotics, as thes

298 indices (P = .01) compared to Ciprofloxacin/Metronidazole with/without systemic antibiotics.

299 in the combination therapy group received IV metronidazole within 48 hours after initiating vancomyci

300 estigate this, we applied the nitroreductase/metronidazole zebrafish model of podocyte injury to in v